ECRI has won the contract to supply the International Horizon Scanning Database

Published on 21 July 2021

ECRI to develop the first large-scale international horizon scanning database of new and promising pharmaceutical products.

ECRI is pleased to announce it has been chosen by IHSI in one of the largest horizon scanning projects of its kind. Our work will enable the early identification and evaluation of promising medicines. ECRI’s findings will help Ireland, Sweden, Norway, Denmark, The Netherlands, Belgium, Portugal and Switzerland to decide which drugs should be covered and at what cost. It currently represents a pharmaceutical spend of over 35 Billion Euros. ECRI will develop a pharmaceutical database and provide high impact reports to facilitate the collaboration between countries on pricing and reimbursement. 

ECRI brings significant experience in assessing new treatment models, procedures, and technologies. ECRI has a track record of building high-quality healthcare information systems and has worked with government agencies, medical associations, and industry bodies since 1968. ECRI serves more than 5,000 customers worldwide.

“ECRI’s independence, evidence-based approach, and advanced use of data science, artificial intelligence, and technology make ECRI an ideal partner,” says Marcus Guardian, general manager, IHSI.

The Belgium-based IHSI launched in 2019 with the aim of pooling resources into the large-scale collection of data on upcoming pharmaceuticals. Eight European countries, representing 73 million people have committed to supporting IHSI, and there is significant interest from several nations further afield. Within these eight countries, national expert bodies collaborate to make IHSI the key vendor of open source, reliable data to support informed decision-making.

Under the terms of the multi-year contract, ECRI will develop, curate, and maintain a database of pharmaceuticals expected to enter the European market within the next two and a half years. ECRI will also create IHSI High Impact Reports which will provide critical insights and information about new medications that show highest potential to disrupt the market.

Both the database and High Impact Reports are expected to level the playing field for stakeholders involved in the decision-making process for the pricing and reimbursement of pharmaceuticals, and may consequently aid potential price negotiations.

“By applying our deep expertise and unbiased objectivity, ECRI will build a high-quality system that IHSI can rely on for the most accurate understanding of the future impact of healthcare technology and drugs,” says Marcus Schabacker, MD, PhD, president and chief executive officer of ECRI. “We look forward to improving access to innovative, safe, and effective medicines for millions of people worldwide.”

Please contact us with any questions on our services including horizon scanning.

See the full IHSI press release here:

Download our full brochure below